Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANVS NASDAQ:ATHE NASDAQ:FGEN OTCMKTS:IMUC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$2.35+1.5%$2.58$1.11▼$10.54$45.70M1.65441,927 shs121,501 shsATHEAlterity Therapeutics$5.16+4.5%$4.83$1.00▼$7.00$45.77M0.4211,394 shs32,763 shsFGENFibroGen$12.18+3.0%$8.07$4.50▼$21.94$49.21M0.7680,846 shs113,794 shsIMUCEOM Pharmaceutical$0.06-32.1%$0.08$0.01▼$0.21$7.72M0.067,901 shs257,096 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio0.00%+3.57%-7.57%-10.97%-72.58%ATHEAlterity Therapeutics0.00%-3.14%-1.40%+6.56%+231.54%FGENFibroGen0.00%+11.29%+71.70%+57.05%+29.43%IMUCEOM Pharmaceutical0.00%-6.33%-9.90%-12.28%-46.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANVSAnnovis Bio1.9718 of 5 stars3.33.00.00.00.61.70.6ATHEAlterity Therapeutics2.6248 of 5 stars3.35.00.00.02.21.70.0FGENFibroGen4.4202 of 5 stars3.33.00.04.72.73.30.6IMUCEOM PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANVSAnnovis Bio 2.60Moderate Buy$18.00667.59% UpsideATHEAlterity Therapeutics 2.50Moderate Buy$12.00132.56% UpsideFGENFibroGen 2.50Moderate Buy$43.00253.04% UpsideIMUCEOM Pharmaceutical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest IMUC, ANVS, FGEN, and ATHE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/8/2025ANVSAnnovis BioZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold8/7/2025FGENFibroGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$43.006/9/2025ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $12.00(Data available from 9/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANVSAnnovis BioN/AN/AN/AN/A$0.67 per shareN/AATHEAlterity TherapeuticsN/AN/AN/AN/A$1.04 per shareN/AFGENFibroGen$29.62M1.66N/AN/A($50.89) per share-0.24IMUCEOM PharmaceuticalN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANVSAnnovis Bio-$24.59M-$2.04N/AN/AN/AN/A-206.01%-158.26%11/14/2025 (Estimated)ATHEAlterity Therapeutics-$12.54MN/A0.00∞N/AN/AN/AN/AN/AFGENFibroGen-$47.58M-$0.38N/AN/AN/A-3.86%N/A-27.34%11/11/2025 (Estimated)IMUCEOM Pharmaceutical-$1.89MN/A0.00∞N/AN/AN/AN/AN/ALatest IMUC, ANVS, FGEN, and ATHE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ANVSAnnovis Bio-$0.36-$0.32+$0.04-$0.32N/AN/A8/11/2025Q2 2025FGENFibroGen-$2.25-$3.38-$1.13-$1.88$2.88 million$1.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANVSAnnovis BioN/AN/AN/AN/AN/AATHEAlterity TherapeuticsN/AN/AN/AN/AN/AFGENFibroGenN/AN/AN/AN/AN/AIMUCEOM PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANVSAnnovis BioN/A7.657.65ATHEAlterity TherapeuticsN/A3.84N/AFGENFibroGenN/A1.041.02IMUCEOM PharmaceuticalN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANVSAnnovis Bio15.83%ATHEAlterity Therapeutics2.14%FGENFibroGen72.71%IMUCEOM PharmaceuticalN/AInsider OwnershipCompanyInsider OwnershipANVSAnnovis Bio20.80%ATHEAlterity Therapeutics38.80%FGENFibroGen1.98%IMUCEOM Pharmaceutical3.28%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANVSAnnovis Bio319.49 million15.43 millionOptionableATHEAlterity Therapeutics108.87 million5.43 millionNot OptionableFGENFibroGen5704.04 million3.96 millionOptionableIMUCEOM Pharmaceutical3126.50 million122.35 millionNot OptionableIMUC, ANVS, FGEN, and ATHE HeadlinesRecent News About These CompaniesQ32 Bio Inc. R (DB0.BE)January 15, 2025 | finance.yahoo.comImmunoCellular Therapeutics, Ltd. (IMUC)January 5, 2024 | uk.finance.yahoo.comEOM Pharmaceutical Holdings Inc.December 29, 2023 | wsj.comEOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613November 7, 2023 | finance.yahoo.comAAO 2023: Apellis unveils data from GALE extension studyNovember 4, 2023 | ophthalmologytimes.comOIZERVAY™ (avacincaptad pegol intravitreal solution) Monthly or Every Other Month Reduced Geographic Atrophy Lesion Growth Through 2 YearsNovember 4, 2023 | markets.businessinsider.comImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives RevenuesNovember 3, 2023 | msn.comOramed Pharmaceuticals Inc ORMPNovember 1, 2023 | morningstar.comMAnalyst Ratings for Olema PharmaceuticalsOctober 11, 2023 | markets.businessinsider.comEOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in BrazilSeptember 6, 2023 | finance.yahoo.comQ2 2023 PAVmed Inc Earnings CallAugust 17, 2023 | uk.finance.yahoo.comEOM Pharmaceuticals shelves plans to uplist shares, raise $15MAugust 3, 2023 | msn.comSYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over ...July 30, 2023 | bakersfield.comBAcumen Pharmaceuticals Announces Proposed Public Offering of Common StockJuly 17, 2023 | benzinga.comFDA rejects Amneal's Parkinson's drugJuly 5, 2023 | beckershospitalreview.comBAmneal Pharmaceuticals: FDA Requests Additional Information on IPX203 IngredientJuly 3, 2023 | marketwatch.comBishop Rehabilitation & Nursing Names Their June 2023 EOMJune 26, 2023 | patch.comAmneal Pharmaceuticals Gets FDA Approval for Injectable Tumor TreatmentJune 14, 2023 | marketwatch.comTrade commission fights Amgen's $28B purchase of Horizon TherapeuticsMay 16, 2023 | msn.comOramed: Q1 Earnings SnapshotMay 12, 2023 | timesunion.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMUC, ANVS, FGEN, and ATHE Company DescriptionsAnnovis Bio NYSE:ANVS$2.35 +0.04 (+1.52%) Closing price 03:58 PM EasternExtended Trading$2.26 -0.08 (-3.41%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Alterity Therapeutics NASDAQ:ATHE$5.16 +0.22 (+4.45%) Closing price 04:00 PM EasternExtended Trading$5.22 +0.06 (+1.24%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.FibroGen NASDAQ:FGEN$12.18 +0.35 (+2.96%) Closing price 04:00 PM EasternExtended Trading$12.06 -0.13 (-1.03%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.EOM Pharmaceutical OTCMKTS:IMUC$0.06 -0.03 (-32.07%) As of 02:32 PM EasternImmunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Kohl’s Stock Rebound Faces a Showdown With Short Sellers What to Watch for From D-Wave Now That Earnings Are Done Alibaba Rallies on New AI Chip Design, Sending NVIDIA Stock Lower 3 High-Yield Stocks Just Supercharged Their Dividends MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
